Clinical trials: Hypercortisolism
Cushing Syndrome
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome.
- Trial name
- NCT03053271
- Testing
- ATR-101
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 4 people
- Sponsor
- Millendo Therapeutics US, Inc.
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Primary Aldosteronism, Hyperaldosteronism
A Study of CIN-107 in Adults With Primary Aldosteronism
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part…
- Trial name
- NCT04605549
- Testing
- CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Congenital Adrenal Hyperplasia, Hyperplasia
Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
This is an open-label, non-randomized, single arm proof-of concept feasibility trial comparing standard oral hydrocortisone (HC) treatment with a six-week intervention of interval bolus delivery (pulsatile) of subcutaneous (SQ)…
- Conditions
- Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders
- Trial name
- NCT03718234
- Testing
- Subcutaneous hydrocortisone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Minnesota
Cushing's Syndrome
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients.
- Trial name
- LINC7 (NCT05633953)
- Testing
- Osilodrostat
- Where
- France
- Volunteers
- 103 people
- Sponsor
- RECORDATI GROUP
Mild Autonomous Cortisol Excess
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and…
- Trial name
- NCT05038878
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Endocrine Disease, Diabetes
Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Background: Metabolic syndrome is a name given to a group of factors that tend to occur together. These risk factors include central obesity (extra weight around the middle of the body) and high blood pressure and blood sugar…
- Trial name
- NCT01419535
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome, Endocrine Disease
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland.
- Trial name
- NCT00001849
- Testing
- Pentetreotide, 18F-DOPA, CT scan
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Obstructive Sleep Apnea, Resistant Hypertension
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Hypertension affects an estimated 60-70 million Americans, predisposing them to potentially life threatening cardiovascular complications.
- Conditions
- Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
- Trial name
- NCT01897727
- Testing
- Spironolactone, BP medication uptitration
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Alabama at Birmingham
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Subclinical Hypercortisolism, Cushing Syndrome
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
Background: Adrenal tumors are a common kind of tumor. Some of these secrete extra cortisol into the body, which can lead to diabetes, obesity, and other diseases.
- Conditions
- Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
- Trial name
- NCT02001051
- Testing
- Adrenalectomy, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
The purpose of the study is to determine the safety and clinical benefit of the combinations of abiraterone acetate and prednisone or abiraterone and dexamethasone in prostate cancer patients.
- Trial name
- NCT01867710
- Testing
- Abiraterone Acetate, Prednisone 5 mg twice daily, Prednisone 5 mg once daily
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 164 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Cushings Disease
Treatment of Cushing's Disease With R-roscovitine
The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.
- Trial name
- NCT02160730
- Testing
- R-roscovitine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shlomo Melmed, MD
Endogenous Cushing's Syndrome
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess…
- Trial name
- NCT03277690
- Testing
- Levoketoconazole
- Where
- 45 sites in United States, Bulgaria and 10 more
- Volunteers
- 84 people
- Sponsor
- Cortendo AB